All In Biotech

Drug Trial Radar · NCT02574286

Study of the Effect of Velaglucerase Alfa (VPRIV®) on Bone-related Pathology in Treatment-naïve Participants With Type 1 Gaucher Disease

An Open-label, Multicenter, Single-arm, Phase 4 Study of the Effect of Treatment With Velaglucerase Alfa on Bone-related Pathology in Treatment-naïve Patients With Type 1 Gaucher Disease

Last checked: Nov 19, 2026Latest source record: Feb 1, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

21

Actual

Start

Jun 29, 2016

Primary completion

Nov 12, 2020

Study completion Nov 30, 2020

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Oct 12, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study is to evaluate the effect of VPRIV therapy (60 units per kilogram \[U/kg\] every other week \[EOW\]) in treatment-naive participants with type 1 Gaucher disease on change from baseline in lumbar spine (LS) bone mineral density (BMD) Z-score as measured by dual energy x-ray absorptiometry (DXA) after 24 months of treatment.

Conditions

  • Gaucher Disease

Interventions

  • Velaglucerase alfaDrug

    Participants will receive 60-minute intravenous infusion of 60 U/kg velaglucerase alfa EOW.

  • Vitamin DDietary supplement

    Participants will receive 800 IU vitamin D orally daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) Z-Score up to End of Study (EOS) (Week 103)Time frame: Baseline up to EOS (Week 103)

Locations

15 sites in 4 countries. Site status is shown where the registry gives one.

  • Cedars Sinai Medical Center

    Beverly Hills, California

  • Kaiser Permanente

    Los Angeles, California

  • Emory Genetics

    Atlanta, Georgia

  • Ann and Robert H Lurie Childrens Hospital of Chicago

    Chicago, Illinois

  • NYU School of Medicine

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • The Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania

  • Lysosomal and Rare Disorders Research and Treatment Center

    Fairfax, Virginia

  • Rambam Health Care Campus

    Haifa, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Rabin Medical Center

    Petah Tikva, Israel

  • Hospital Universitario Ramon y Cajal

    Madrid, Spain

  • Hospital Quironsalud Zaragoza

    Zaragoza, Spain

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

  • Royal Free Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.